Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.85
BIOTRICITY INC. reported fiscal 2023 year and (unaudited) fourth quarter ended March 31, 2023 results: revenue $9.64 million, net income $19.5 million, EPS $0.38 per share.
- Period
- fiscal 2023 year and (unaudited) fourth quarter ended March 31, 2023
- Revenue
- $9.64 million
- Net income
- $19.5 million
- EPS
- $0.38 per share
- Result
- reported results
Exact text from the filing
Cash Flow ● Company advancing toward positive cashflow likely by end of CY 2024 ● Accelerating product sales, and customer re-order revenue, ● FY23 revenue rose 26% YOY to $9.64 million on 5% lower SG&A of $17.6 million ● Improving gross margins currently at 57% despite reduced, loss-leader device pricing to boost recurring ‘Technology Fees,’ lower customers’
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
BIOTRICITY INC.: Effected a 1-for-6 reverse stock split via Certificate of Amendment to Amended and Restated Articles of Incorporation (effective 2023-07-03).
- Change
- charter amendment
- Effective
- 2023-07-03
Exact text from the filing
On June 29, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation to effect a one-for-six (1-for-6) reverse split (the “Reverse Split”). The Reverse Split became effective on July 3, 2023.
View on SEC.gov